RNTX Company Profile and Key Details

RNTX has shown mixed momentum, gaining 4.35% over the past week and -1.64% over the past quarter, though year-to-date performance is up 3.45%. Short-term trend indicators are bullishly aligned (SMA20 0.04%, SMA50 -3.83%, SMA200 -14.28%). The stock’s 14-day RSI is 48.32 (neutral), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -53.84% below its high and over 17.65% above its low. Average 10-day trading volume of 402.41 thousand shares is below the 3-month average of 650.85 thousand, indicating normal recent market interest.

Rein Therapeutics Inc. generated EPS of -$2.64 over the past year. Five-year average earnings growth is 31.9%. Wall Street analysts project EPS growth of 36.0% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $4.00. The high target offers 1023.6% upside. The low target suggests 349.44% downside. The mean target is $7.33. This offers 723.6% upside. Rein Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended May 15, 2026, missed forecasts by -61.22%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 310.68% in December 31, 2024.

Rein Therapeutics Inc. has 23.05 million shares outstanding. The public float is 19.75 million shares, elevated short interest at 0.22% of float. This equals 51.48 thousand shares. The short ratio is 1.04 days. Institutional investors hold 22.07% of the float. Insiders own 5.5%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Rein Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.13. This means the shares are trading above this model’s fair value.

Rein Therapeutics Inc. (NASDAQ:RNTX) shares are flat 3.45% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Rein Therapeutics Inc. trading at a premium to the broader market with a P/E of -0.48. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.33, suggesting 719.18% upside. Our AI forecast model points to short-term weakness (-5.01% over two weeks), a medium-term fall (-32.95% over three months), and a longer-term gain (1841.22% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Rein Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.01%, with price expected at $0.85 by August 04, 2026, within a range of $0.78 to $0.92 3-Month Outlook: Projected fall of -32.95%, reaching $0.60 by October 19, 2026, with a range of $0.51 to $0.68. 1-Year Outlook: Projected gain of 1841.22%, with price at $17.37 by July 21, 2027, within a range of $16.42 to $19.53.

Rein Therapeutics Inc. trades at a P/E ratio of -0.48, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.41 suggesting the stock is closer to book value. The P/FCF stands at -1.55, also above market averages.

Rein Therapeutics Inc. (NASDAQ:RNTX) closed at $0.86 USD, losing -$0.03 (-3.88%) from the previous close of $0.89. The stock is currently within 5% of its 52-week low $0.83 and $2.18. With a market capitalization of about $24.04 million, Rein Therapeutics Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.35). Key stats such as the average daily volume over the past year has been around 834.06 thousand shares, volume is running light vs its 52-week average. Headquartered in Austin, TX, Rein Therapeutics Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO James Brian Windsor, the company employs approximately 10 people and listed since June 29, 2017. Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer.